MicroPort Scientific Corporation Total Assets
MicroPort Scientific Corporation total assets. Based on the latest financial reports, MicroPort Scientific Corporation (MSK) holds total assets worth €3.70 Billion EUR (≈ $4.32 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MicroPort Scientific Corporation (MSK) total market value for the company's overall valuation and market capitalisation.
Total Assets of MicroPort Scientific Corporation (2013–2025)
Total assets of MicroPort Scientific Corporation from 2013 to 2025. This chart illustrates how MicroPort Scientific Corporation's total assets have evolved over time, based on quarterly financial data. See MicroPort Scientific Corporation stock price for real-time trading data and today's change.
MicroPort Scientific Corporation - Asset Composition Analysis
MicroPort Scientific Corporation Total Assets Breakdown (December 2025)
MicroPort Scientific Corporation total assets breakdown as of December 2025. MicroPort Scientific Corporation's total assets of €3.70 Billion consist of 44.2% current assets and 55.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 18.5% |
| Accounts Receivable | €328.07 Million | 8.9% |
| Inventory | €349.20 Million | 9.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €183.31 Million | 5.0% |
| Goodwill | €201.11 Million | 5.4% |
Asset Composition Trend (2013–2025)
This chart illustrates how MicroPort Scientific Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore MicroPort Scientific Corporation working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MicroPort Scientific Corporation's current assets represent 44.2% of total assets in 2025, a decrease from 57.8% in 2013.
- Cash Position: Cash and equivalents constituted 18.5% of total assets in 2025, down from 30.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 5.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 9.5% of total assets.
MicroPort Scientific Corporation Competitors by Total Assets
Key competitors of MicroPort Scientific Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
MicroPort Scientific Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.45 | 1.47 | 2.85 |
| Quick Ratio | 1.14 | 1.15 | 2.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €504.52 Million | €558.26 Million | €960.48 Million |
MicroPort Scientific Corporation - Advanced Valuation Insights
This section examines the relationship between MicroPort Scientific Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.12 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 1.7% |
| Total Assets | €3.70 Billion |
| Market Capitalization | $1.45 Billion USD |
Valuation Analysis
Below Book Valuation: The market values MicroPort Scientific Corporation's assets below their book value (0.39x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: MicroPort Scientific Corporation's assets grew by 1.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for MicroPort Scientific Corporation (2013–2025)
The table below shows the annual total assets of MicroPort Scientific Corporation from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €3.70 Billion ≈ $4.32 Billion |
+1.74% |
| 2024-12-31 | €3.63 Billion ≈ $4.25 Billion |
-7.60% |
| 2023-12-31 | €3.93 Billion ≈ $4.60 Billion |
-1.54% |
| 2022-12-31 | €3.99 Billion ≈ $4.67 Billion |
-8.82% |
| 2021-12-31 | €4.38 Billion ≈ $5.12 Billion |
+77.41% |
| 2020-12-31 | €2.47 Billion ≈ $2.89 Billion |
+54.52% |
| 2019-12-31 | €1.60 Billion ≈ $1.87 Billion |
+25.38% |
| 2018-12-31 | €1.27 Billion ≈ $1.49 Billion |
+41.04% |
| 2017-12-31 | €903.62 Million ≈ $1.06 Billion |
+16.66% |
| 2016-12-31 | €774.55 Million ≈ $905.53 Million |
+5.58% |
| 2015-12-31 | €733.64 Million ≈ $857.71 Million |
-21.93% |
| 2014-12-31 | €939.73 Million ≈ $1.10 Billion |
+81.12% |
| 2013-12-31 | €518.85 Million ≈ $606.59 Million |
-- |
About MicroPort Scientific Corporation
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; an… Read more